Bulletin
Investor Alert

Novavax Inc.

NAS: NVAX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 25, 2020, 7:59 p.m.

/zigman2/quotes/202614340/composite

$

113.00

Change

-0.56 -0.49%

Volume

Volume 60,163

Quotes are delayed by 20 min

/zigman2/quotes/202614340/composite

Previous close

$ 102.44

$ 113.56

Change

+11.12 +10.86%

Day low

Day high

$105.80

$117.35

Open

52 week low

52 week high

$3.54

$189.40

Open

Company Description

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant...

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Valuation

Price to Sales Ratio

5.14

Enterprise Value to Sales

18.54

Total Debt to Enterprise Value

0.96

Efficiency

Revenue/Employee

113,103.00

Income Per Employee

-804,206.00

Receivables Turnover

4.98

Total Asset Turnover

0.10

Liquidity

Current Ratio

3.77

Quick Ratio

3.77

Cash Ratio

3.17

Profitability

Operating Margin

-694.44

Pretax Margin

-711.04

Net Margin

-711.04

Return on Assets

-69.67

Return on Total Capital

-87.24

Return on Invested Capital

-89.70

Capital Structure

Total Debt to Total Capital

227.53

Total Debt to Total Assets

191.88

Long-Term Debt to Total Capital

226.67

Officers and Executives

Name Age Officer Since Title
Mr. Stanley C. Erck 71 2009 Director
Mr. John J. Trizzino 59 2009 Senior Vice President-Business Development
Mr. Biegie Lee - - Vice President-Information Technology
Dr. Gale E. Smith - - Chief Scientist, VP-Pre-Clinical Research
Mr. Filip Dubovsky - 2020 Chief Medical Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/18/2020 Gary C. Evans
Director
10,500   Disposition at $150.44 per share. 1,579,620
08/18/2020 Michael A. McManus
Director
8,000   Disposition at $146 per share. 1,168,000
08/18/2020 John J. Trizzino
EVP, CBO and CFO
1,300   Disposition at $153.95 per share. 200,135
08/18/2020 John J. Trizzino
EVP, CBO and CFO
1,708   Disposition at $153.16 per share. 261,597
08/18/2020 John J. Trizzino
EVP, CBO and CFO
4,199   Disposition at $152.22 per share. 639,171
08/18/2020 John J. Trizzino
EVP, CBO and CFO
4,010   Disposition at $150.85 per share. 604,908
08/18/2020 John J. Trizzino
EVP, CBO and CFO
1,800   Disposition at $149.83 per share. 269,694
08/18/2020 John J. Trizzino
EVP, CBO and CFO
6,600   Disposition at $149.08 per share. 983,928
08/18/2020 John J. Trizzino
EVP, CBO and CFO
9,101   Disposition at $147.99 per share. 1,346,856
08/18/2020 John J. Trizzino
EVP, CBO and CFO
8,094   Disposition at $146.95 per share. 1,189,413
08/18/2020 John J. Trizzino
EVP, CBO and CFO
4,900   Disposition at $146.21 per share. 716,429
08/18/2020 John J. Trizzino
EVP, CBO and CFO
300   Disposition at $143.99 per share. 43,197
08/18/2020 John J. Trizzino
EVP, CBO and CFO
776   Disposition at $142.85 per share. 110,851
08/18/2020 Gregory M. Glenn
President, R&D
525   Disposition at $146.58 per share. 76,954
08/18/2020 Gregory M. Glenn
President, R&D
17,151   Disposition at $146 per share. 2,504,046
08/18/2020 Gregory M. Glenn
President, R&D
31,957   Disposition at $145 per share. 4,633,765
08/18/2020 Gregory M. Glenn
President, R&D
6,288   Disposition at $143.94 per share. 905,094
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
21,648   Disposition at $144.79 per share. 3,134,413
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
24,594   Disposition at $143.92 per share. 3,539,568
08/18/2020 Gregory M. Glenn
President, R&D
1,528   Gift at $0 per share. 0
08/18/2020 Gary C. Evans
Director
4,000   Derivative/Non-derivative trans. at $27.6 per share. 110,400
08/18/2020 Gary C. Evans
Director
4,000   Derivative/Non-derivative trans. at $27.6 per share. 110,400
08/18/2020 Gary C. Evans
Director
1,500   Derivative/Non-derivative trans. at $36.6 per share. 54,900
08/18/2020 Gary C. Evans
Director
1,000   Derivative/Non-derivative trans. at $50 per share. 50,000
08/18/2020 Michael A. McManus
Director
4,000   Derivative/Non-derivative trans. at $27.6 per share. 110,400
08/18/2020 Michael A. McManus
Director
4,000   Derivative/Non-derivative trans. at $27.6 per share. 110,400
08/18/2020 John J. Trizzino
EVP, CBO and CFO
10,410   Derivative/Non-derivative trans. at $46 per share. 478,860
08/18/2020 John J. Trizzino
EVP, CBO and CFO
13,322   Derivative/Non-derivative trans. at $27.6 per share. 367,687
08/18/2020 John J. Trizzino
EVP, CBO and CFO
1,952   Derivative/Non-derivative trans. at $27 per share. 52,704
08/18/2020 John J. Trizzino
EVP, CBO and CFO
5,855   Derivative/Non-derivative trans. at $27 per share. 158,085
08/18/2020 John J. Trizzino
EVP, CBO and CFO
11,249   Derivative/Non-derivative trans. at $99.8 per share. 1,122,650
08/18/2020 Gregory M. Glenn
President, R&D
13,225   Derivative/Non-derivative trans. at $46 per share. 608,350
08/18/2020 Gregory M. Glenn
President, R&D
16,658   Derivative/Non-derivative trans. at $27.6 per share. 459,760
08/18/2020 Gregory M. Glenn
President, R&D
2,733   Derivative/Non-derivative trans. at $27 per share. 73,791
08/18/2020 Gregory M. Glenn
President, R&D
8,200   Derivative/Non-derivative trans. at $27 per share. 221,400
08/18/2020 Gregory M. Glenn
President, R&D
4,405   Derivative/Non-derivative trans. at $36.6 per share. 161,223
08/18/2020 Gregory M. Glenn
President, R&D
7,500   Derivative/Non-derivative trans. at $25.6 per share. 192,000
08/18/2020 Gregory M. Glenn
President, R&D
3,200   Derivative/Non-derivative trans. at $50 per share. 160,000
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
8,328   Derivative/Non-derivative trans. at $46 per share. 383,088
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
13,322   Derivative/Non-derivative trans. at $27.6 per share. 367,687
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
1,952   Derivative/Non-derivative trans. at $27 per share. 52,704
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
393   Derivative/Non-derivative trans. at $27 per share. 10,611
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
11,249   Derivative/Non-derivative trans. at $99.8 per share. 1,122,650
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
2,499   Derivative/Non-derivative trans. at $91 per share. 227,409
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
7,499   Derivative/Non-derivative trans. at $36.6 per share. 274,463
08/18/2020 John A. Herrmann
EVP, Chief Legal Officer
1,000   Derivative/Non-derivative trans. at $50 per share. 50,000
06/18/2020 Gregory M. Glenn
President, R&D
16,749   Disposition at $59.53 per share. 997,067
06/18/2020 Gregory M. Glenn
President, R&D
16,749   Derivative/Non-derivative trans. at $42.2 per share. 706,807
06/03/2020 James F. Young
Director
1,500   Acquisition at $48.83 per share. 73,245
05/18/2020 John A. Herrmann
EVP, Chief Legal Officer
5,462   Disposition at $49.44 per share. 270,041
05/18/2020 John A. Herrmann
EVP, Chief Legal Officer
7,499   Disposition at $49.44 per share. 370,750
05/18/2020 John A. Herrmann
EVP, Chief Legal Officer
5,462   Derivative/Non-derivative trans. at $27 per share. 147,474
05/18/2020 John A. Herrmann
EVP, Chief Legal Officer
7,499   Derivative/Non-derivative trans. at $25.6 per share. 191,974
03/08/2020 Stanley C. Erck
President and CEO; Director
1,992   Derivative/Non-derivative trans. at $12.48 per share. 24,860
03/08/2020 John J. Trizzino
EVP, CBO and CFO
181   Derivative/Non-derivative trans. at $12.48 per share. 2,258
03/08/2020 Gregory M. Glenn
President, R&D
294   Derivative/Non-derivative trans. at $12.48 per share. 3,669
03/08/2020 John A. Herrmann
EVP, Chief Legal Officer
174   Derivative/Non-derivative trans. at $12.48 per share. 2,171
03/08/2020 Stanley C. Erck
President and CEO; Director
6,072   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2020 John J. Trizzino
EVP, CBO and CFO
468   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2020 Gregory M. Glenn
President, R&D
760   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2020 John A. Herrmann
EVP, Chief Legal Officer
449   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Gregory M. Glenn
President, R&D
1,250   Acquisition at $3.86 per share. 4,825
11/18/2019 Michael A. McManus
Director
3,929   Disposition at $3.82 per share. 15,008
09/17/2019 John A. Herrmann
EVP, Chief Legal Officer
3,643   Disposition at $7.07 per share. 25,756
09/13/2019 Gregory M. Glenn
President, R&D
9,620   Disposition at $6.18 per share. 59,451
09/11/2019 John J. Trizzino
EVP, CBO and CFO
5,578   Disposition at $5.72 per share. 31,906
/news/latest/company/us/nvax

MarketWatch News on NVAX

  1. The Pandemic Speeds Up the Health-Care Revolution

    8:37 p.m. Sept. 25, 2020

    - Lauren R. Rublin

  2. Tech Stocks Stand Out as Rough Week Ends

    4:28 p.m. Sept. 25, 2020

    - Alexandra Scaggs,

  3. Covid-19 Vaccine Prices May Be Unexpectedly Low

    1:30 p.m. Sept. 25, 2020

    - Bill Alpert

  4. Novavax Starts a Phase 3 Trial of Its Covid-19 Vaccine

    9:07 a.m. Sept. 25, 2020

    - Bill Alpert

  5. Covid-19 Is Thwarting Progress on Poverty and Inequality

    3:07 p.m. Sept. 15, 2020

    - Abby Schultz

  6. AstraZeneca’s Vaccine-Trial Pause Won’t Slow Its Rivals

    9:18 a.m. Sept. 9, 2020

    - Bill Alpert

  7. Loading more headlines...
/news/nonmarketwatch/company/us/nvax

Other News on NVAX

  1. Stocks To Watch: Alibaba, PepsiCo, Wayfair And Palantir

    36 min ago

    - Seeking Alpha

  2. U.S. Coronavirus Cases Rise, and Surpass Seven Million

    10:52 p.m. Sept. 25, 2020

    - Adam Martin

  3. Seeking Alpha Catalyst Watch

    3:30 p.m. Sept. 25, 2020

    - Seeking Alpha

  4. Covid-19 Vaccines: What’s Coming and When?

    3:13 p.m. Sept. 25, 2020

    - Ana Rivas

  5. NVAX Stock: Novavax Rallies After Entering Phase 3 Vaccine Trials

    1:00 p.m. Sept. 25, 2020

    - InvestorPlace.com

  6. Sell-siders gush over Novavax COVID-19 study

    8:59 a.m. Sept. 25, 2020

    - Seeking Alpha

  7. NVAX, CLNY among premarket gainers

    8:19 a.m. Sept. 25, 2020

    - Seeking Alpha

  8. Covid-19 Vaccine From Novavax to Begin Phase 3 Trial in U.K.

    11:29 p.m. Sept. 24, 2020

    - Peter Loftus

  9. Rollercoaster Market for Thursday

    5:47 p.m. Sept. 24, 2020

    - Zacks.com

  10. Novavax initiates pivotal study of COVID-19 vaccine candidate

    4:17 p.m. Sept. 24, 2020

    - Seeking Alpha

  11. Loading more headlines...

At a Glance

Novavax, Inc.

20 Firstfield Road

Gaithersburg, Maryland 20878

Phone

1 2402682000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$18.66M

Net Income

$-132.69M

Employees

165.00

/news/pressrelease/company/us/nvax

Press Releases on NVAX

  1. Novavax into Clinical Trials

    10:00 a.m. Sept. 25, 2020

    - Baystreet.ca

  2. Vaccine Updates

    10:12 a.m. Sept. 24, 2020

    - IAM Newswire

  3. Loading more headlines...
Link to MarketWatch's Slice.